	US 12,234,282 B2
	Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
Dong Feng Chen, Newtonville, MA (US); Ji Min, Boston, MA (US); and Kin-Sang Cho, Boston, MA (US)
Assigned to The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed by The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed on May 16, 2023, as Appl. No. 18/318,336.
Application 18/318,336 is a continuation of application No. 16/977,783, granted, now 11,692,029, previously published as PCT/US2019/020787, filed on Mar. 5, 2019.
Claims priority of provisional application 62/638,884, filed on Mar. 5, 2018.
Prior Publication US 2024/0025986 A1, Jan. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 38/19 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/243 (2013.01) [A61K 9/0048 (2013.01); A61K 38/193 (2013.01); C07K 16/2866 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01)]

18 Claims

1. A method for preventing visual function loss in a subject with glaucoma, comprising intravitreally administering to the subject a neutralizing antibody that specifically binds colony stimulating factor-1 receptor (CSF1R).